Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

In childhood leukemia study, aggressive chemotherapy cuts deaths by 37%

02.10.2003


More than a third of children who die from a particularly deadly form of leukemia would be saved if doctors used three existing drugs more aggressively – administering them at much higher doses and over a longer period of time. That is one of several important conclusions drawn from a long-term study, published in the October issue of the Journal of Clinical Oncology, that tested a high-dose drug regimen in 125 young leukemia patients and tracked their outcomes for an average of nine years.



The study, conducted by researchers at nine universities and research hospitals, was led by Barbara L. Asselin, M.D., associate professor of Pediatrics and Oncology at the James P. Wilmot Cancer Center at the University of Rochester. It focused on children with T-cell acute lymphoblastic leukemia, or T-ALL, which accounts for 15 percent of all childhood leukemia cases and is fatal in nearly four in 10 children. While dozens of drugs are routinely used to treat children with the disease, the study sheds new light on the fundamental questions about their use: Which combination of those drugs is most effective? And, what are the highest doses that can be given without subjecting children to additional risks – such as kidney damage and neurological problems – that might be caused by the powerful drugs themselves?

To find out, the researchers drew on earlier studies that had pointed to the effectiveness of three cancer-killing drugs – methotrexate, asparaginase, and doxorubicin. The researchers devised an experimental regimen in which all three would be administered at whopping doses – up to five times higher than usual – and for durations of several months instead of weeks. Between 1981 and 2000, 125 children with T-ALL received the experimental treatment. Afterward, each patient’s progress was followed by the researchers for an average of nine years. More than 25 percent of the patients were followed into their 20s, and some into their early 30s. The researchers were interested not only in whether the children survived the cancer, but also whether the high-dose chemotherapy produced any debilitating long-term effects.


Of the 125 children studied, 93 of them were cured, yielding a survival rate of 75 percent compared to survival rates of between 60 and 65 percent for treatment regimens that used much lower drug doses. Years after treatment, despite the more aggressive chemotherapy, the patients did not experience medical problems beyond those reported in those who had received lower doses of the drugs, with one exception. Patients who had received higher doses of doxorubicin experienced slightly higher rates of cardiomyopathy, a weakening of the heart muscle that can usually be controlled with medication.

"This study tells us, without question, that we should be using these drugs much more aggressively," said Asselin. "Giving these drugs at much higher dosages dramatically improves a child’s chances for survival, and does not pose a significantly greater risk for long-term negative effects. The evidence is so compelling that we are recommending that this new approach become the standard treatment for all children diagnosed with this form of leukemia."

In addition to high-dose chemotherapy, children in the study received low-dose radiation therapy to the brain, where cancerous cells are most likely to survive chemotherapy and cause a relapse of leukemia in the future. Asselin and her colleagues credit the combination of chemotherapy and radiation with preventing relapse among the majority of children in the study, thereby minimizing the greatest threat to their long-term survival. Equally important, the use of low-dose radiation to the brain did not result in a decline in cognitive abilities that had been reported in earlier studies in which children had received higher does of radiation.

"Our goal in this study, and in our careers as researchers, is to find the right balance of treatment for these children," said Asselin. "We want to deliver treatment that is powerful enough to kill their cancer, yet not so toxic that the treatment itself robs them of a normal life afterward. We want them to be healthy – to grow up to play and have fun and do well in school and have a normal quality of life."

The study was funded by the National Institutes of Health and conducted by the Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium. Co-authors of the paper were John M. Goldberg, Lewis B. Silverman, Donna E. Levy, Virginia Kimball Dalton, Richard D. Gelber, Leslie Lehmann, Harvey J. Cohen, and Stephen E. Sallan.

Chris DiFrancesco | EurekAlert!
Further information:
http://www.urmc.rochester.edu/

More articles from Health and Medicine:

nachricht Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania

nachricht The strange double life of Dab2
10.01.2017 | University of Miami Miller School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

Im Focus: Bacterial Pac Man molecule snaps at sugar

Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.

The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...

Im Focus: Newly proposed reference datasets improve weather satellite data quality

UMD, NOAA collaboration demonstrates suitability of in-orbit datasets for weather satellite calibration

"Traffic and weather, together on the hour!" blasts your local radio station, while your smartphone knows the weather halfway across the world. A network of...

Im Focus: Repairing defects in fiber-reinforced plastics more efficiently

Fiber-reinforced plastics (FRP) are frequently used in the aeronautic and automobile industry. However, the repair of workpieces made of these composite materials is often less profitable than exchanging the part. In order to increase the lifetime of FRP parts and to make them more eco-efficient, the Laser Zentrum Hannover e.V. (LZH) and the Apodius GmbH want to combine a new measuring device for fiber layer orientation with an innovative laser-based repair process.

Defects in FRP pieces may be production or operation-related. Whether or not repair is cost-effective depends on the geometry of the defective area, the tools...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

Multiregional brain on a chip

16.01.2017 | Power and Electrical Engineering

New technology enables 5-D imaging in live animals, humans

16.01.2017 | Information Technology

Researchers develop environmentally friendly soy air filter

16.01.2017 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>